Kimberly Dahlman
Last active: 2/13/2015

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS (2015) Cancer Cell 27(2): 240-56
    › Primary publication · 25600339 (PubMed) · PMC4326539 (PubMed Central)
  2. Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism. Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM (2015) Exp Hematol 43(2): 74-8
    › Primary publication · 25448491 (PubMed) · PMC5002942 (PubMed Central)
  3. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W (2014) Oncologist 19(6): 616-22
    › Primary publication · 24797823 (PubMed) · PMC4041676 (PubMed Central)
  4. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z (2014) Mol Cancer Ther 13(7): 1918-28
    › Primary publication · 24755198 (PubMed) · PMC4090262 (PubMed Central)
  5. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL (2014) Breast Cancer Res Treat 145(2): 389-99
    › Primary publication · 24722917 (PubMed) · PMC4046906 (PubMed Central)
  6. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W (2014) Clin Cancer Res 20(9): 2264-75
    › Primary publication · 24599935 (PubMed) · PMC4008689 (PubMed Central)
  7. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL (2014) Breast Cancer Res 16(1): R9
    › Primary publication · 24451154 (PubMed) · PMC3978602 (PubMed Central)
  8. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS (2014) Cancer Discov 4(1): 80-93
    › Primary publication · 24265155 (PubMed) · PMC3936420 (PubMed Central)
  9. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z (2013) Genome Med 5(10): 91
    › Primary publication · 24112718 (PubMed) · PMC3971343 (PubMed Central)
  10. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W (2013) Genome Res 23(9): 1434-45
    › Primary publication · 23733853 (PubMed) · PMC3759720 (PubMed Central)
  11. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W (2012) Cancer Discov 2(9): 791-7
    › Primary publication · 22798288 (PubMed) · PMC3449158 (PubMed Central)
  12. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS (2012) Cancer Discov 2(5): 414-24
    › Primary publication · 22588879 (PubMed) · PMC3594852 (PubMed Central)
  13. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W (2012) PLoS One 7(4): e35309
    › Primary publication · 22536370 (PubMed) · PMC3335021 (PubMed Central)
  14. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL (2012) PLoS One 7(4): e34414
    › Primary publication · 22509301 (PubMed) · PMC3324507 (PubMed Central)
  15. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS (2012) Nat Commun : 724
    › Primary publication · 22395615 (PubMed) · PMC3530385 (PubMed Central)
  16. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
  17. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) Nature 480(7377): 387-90
    › Primary publication · 22113612 (PubMed) · PMC3266695 (PubMed Central)
  18. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL (2011) Nature 471(7339): 523-6
    › Primary publication · 21430781 (PubMed) · PMC3541675 (PubMed Central)